Prajwal P Nandekar

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7281549/prajwal-p-nandekar-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31	397	13	18
papers	citations	h-index	g-index
34	472 ext. citations	3.9	3.54
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
31	An electron transfer competent structural ensemble of membrane-bound cytochrome P450 1A1 and cytochrome P450 oxidoreductase. <i>Communications Biology</i> , 2021 , 4, 55	6.7	10
30	The Effect of Force-Field Parameters on Cytochrome P450-Membrane Interactions: Structure and Dynamics. <i>Scientific Reports</i> , 2020 , 10, 7284	4.9	14
29	Differing Membrane Interactions of Two Highly Similar Drug-Metabolizing Cytochrome P450 Isoforms: CYP 2C9 and CYP 2C19. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	6
28	Influence of Transmembrane Helix Mutations on Cytochrome P450-Membrane Interactions and Function. <i>Biophysical Journal</i> , 2019 , 116, 419-432	2.9	13
27	A Multi-resolution Approach to the Simulation of Protein Complexes in a Membrane Bilayer 2019 , 505	-514	
26	Ligand tunnels in T. brucei and human CYP51: Insights for parasite-specific drug design. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016 , 1860, 67-78	4	18
25	An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. <i>Biomedical Chromatography</i> , 2016 , 30, 1556-72	1.7	8
24	Synthesis and biology of ring-modified l-Histidine containing thyrotropin-releasing hormone (TRH) analogues. <i>European Journal of Medicinal Chemistry</i> , 2016 , 111, 72-83	6.8	4
23	Dynathor: Dynamics of the Complex of Cytochrome P450 and Cytochrome P450 Reductase in a Phospholipid Bilayer 2016 , 255-264		2
22	Characterization of differences in substrate specificity among CYP1A1, CYP1A2 and CYP1B1: an integrated approach employing molecular docking and molecular dynamics simulations. <i>Journal of Molecular Recognition</i> , 2016 , 29, 370-90	2.6	11
21	Structure guided design and binding analysis of EGFR inhibiting analogues of erlotinib and AEE788 using ensemble docking, molecular dynamics and MM-GBSA. <i>RSC Advances</i> , 2016 , 6, 65725-65735	3.7	27
20	Identification of leads for antiproliferative activity on MDA-MB-435 human breast cancer cells through pharmacophore and CYP1A1-mediated metabolism. <i>European Journal of Medicinal Chemistry</i> , 2016 , 115, 82-93	6.8	9
19	Discovery of a low affinity thyrotropin-releasing hormone (TRH)-like peptide that exhibits potent inhibition of scopolamine-induced memory impairment in mice. <i>RSC Advances</i> , 2015 , 5, 56872-56884	3.7	4
18	Synthesis of CNS active thyrotropin-releasing hormone (TRH)-like peptides: Biological evaluation and effect on cognitive impairment induced by cerebral ischemia in mice. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 5641-53	3.4	9
17	Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 102, 386-99	3.5	18
16	On the application of the MARTINI coarse-grained model to immersion of a protein in a phospholipid bilayer. <i>Journal of Chemical Physics</i> , 2015 , 143, 243139	3.9	15
15	Ensemble docking and molecular dynamics identify knoevenagel curcumin derivatives with potent anti-EGFR activity. <i>Gene</i> , 2014 , 539, 82-90	3.8	31

LIST OF PUBLICATIONS

14	Characterization of forced degradation products of ketorolac tromethamine using LC/ESI/Q/TOF/MS/MS and in silico toxicity prediction. <i>Journal of Mass Spectrometry</i> , 2014 , 49, 380-91	2.2	11	
13	Comparative proteomics among cytochrome p450 family 1 for differential substrate specificity. <i>Protein Journal</i> , 2014 , 33, 536-48	3.9	6	
12	Design and synthesis of optically pure 3-aryl-6-methyl-2-thioxotetrahydropyrimidin-4(1H)-ones as anti-prostate cancer agents. <i>RSC Advances</i> , 2014 , 4, 37868-37877	3.7	5	
11	Intestinal transport of TRH analogs through PepT1: the role of in silico and in vitro modeling. <i>Journal of Molecular Recognition</i> , 2014 , 27, 609-17	2.6	6	
10	Predicting drug metabolism by CYP1A1, CYP1A2, and CYP1B1: insights from MetaSite, molecular docking and quantum chemical calculations. <i>Molecular Diversity</i> , 2014 , 18, 865-78	3.1	14	
9	Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management. <i>Molecular Diversity</i> , 2014 , 18, 895-909	3.1	12	
8	Human pregnane X receptor: a novel target for anticancer drug development. <i>Drug Discovery Today</i> , 2014 , 19, 63-70	8.8	4	
7	Molecular dynamics simulation studies for DNA sequence recognition by reactive metabolites of anticancer compounds. <i>Journal of Molecular Recognition</i> , 2014 , 27, 138-50	2.6	6	
6	Chem-bioinformatics and in vitro approaches for candidate optimization: a case study of NSC745689 as a promising antitumor agent. <i>Medicinal Chemistry Research</i> , 2013 , 22, 3728-3742	2.2	17	
5	Impact of Crystal Habit on Biopharmaceutical Performance of Celecoxib. <i>Crystal Growth and Design</i> , 2013 , 13, 2824-2832	3.5	61	
4	Cytochrome P450 1A1-mediated anticancer drug discovery: in silico findings. <i>Expert Opinion on Drug Discovery</i> , 2012 , 7, 771-89	6.2	20	
3	An ecofriendly synthesis and DNA binding interaction study of some pyrazolo [1,5-a]pyrimidines derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 7566-72	2.9	20	
2	Mechanistic insights into PEPT1-mediated transport of a novel antiepileptic, NP-647. <i>Molecular Pharmaceutics</i> , 2012 , 9, 2458-68	5.6	13	
1	An electron transfer competent structural ensemble of membrane-bound cytochrome P450 1A1 and cytochrome P450 oxidoreductase		3	